

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Unassigned
Phillip Monk, et al.)	Art Unit: 1644
Application Serial No. 10/564,647)	Confirmation No. 1467
Filed: July 19, 2006)	Attorney's Docket No. 43518-0001 PC US
For: Human Antibody Molecules for IL-13)	Customer No. 25213

EXPRESS MAIL NO. EV 766 021 212 US
DATE MAILED: June 22, 2007

PRELIMINARY AMENDMENT

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Prior to consideration of the above-identified patent application please enter the following amendments and consider the following remarks. Applicants also enclose herewith an Information Disclosure Statement. Applicants enclose herewith revised Table 1. Applicants enclose herewith a paper copy of the Sequence Listing, an electronic copy of the Sequence Listing, and a Statement Under 37 CFR §1.821.

Amendments to the specification begin on page 2 of this paper.

Amendments to the claims begin on page 3 of this paper.

Remarks/Arguments begin on page 14 of this paper.